Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients

Ryutaro Ishitsuka, Jun Miyazaki, Daishi Ichioka, Takamitsu Inoue, Susumu Kageyama, Mikio Sugimoto, Koji Mitsuzuka, Yoshiyuki Matsui, Yusuke Shiraishi, Hidefumi Kinoshita, Hironobu Wakeda, Takeshi Nomoto, Eiji Kikuchi, Koji Kawai, Hiroyuki Nishiyama

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: The Kidney Disease: Improving Global Outcomes group (KDIGO) defined acute kidney injury (AKI) as an elevation of serum creatinine (sCR) exceeding 0.3 mg/dl within 48 h. The widely used adverse events criteria for chemotherapy, Common Toxicity Criteria for Adverse Events Version 4.0 (CTCAE v4.0), also defined AKI as sCR exceeding 0.3 mg/dl, but with no provision of a time course. Here, we attempted to clarify the impact of AKI (CTCAE v4.0) during cisplatin-based chemotherapy on clinical outcome of patients with advanced urothelial cancer (UC). Methods: This multicenter retrospective study included 230 UC patients who received cisplatin-based chemotherapy. Results: During the first chemotherapy course, AKI (CTCAE v4.0) episodes were observed in 61 patients (26.5 %), whereas only four patients (1.5 %) experienced AKI (KDIGO) episodes. Both the pretreatment estimated glomerular filtration rate (eGFR) and creatinine clearance by Cockcroft–Gault formula were not efficient predictors for the development of AKI (CTCAE v4.0). AKI (CTCAE v4.0) impacted renal function: at the start of second-course chemotherapy, the average eGFR of the patients with AKI (CTCAE v4.0) was 54.1 ml/min/1.73 m2, significantly lower than that of patients without AKI (CTCAE v4.0) (63.4 ml/min/1.73 m2). As a result, only 57.4 % of patients with AKI (CTCAE v4.0) received the planned treatment at the second course. The survival of the patients who developed AKI (CTCAE v4.0) was significantly worse than that of the patients who did not. The 3-year OSs were 10.3 and 21.4 %, respectively (P = 0.02). Conclusion: The present study demonstrated that AKI (CTCAE v4.0) during chemotherapy had a negative impact on both the intensity of subsequent chemotherapy and oncological outcomes.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalClinical and Experimental Nephrology
DOIs
Publication statusAccepted/In press - 2016 Aug 26

Fingerprint

Acute Kidney Injury
Cisplatin
Drug Therapy
Neoplasms
Creatinine
Kidney Diseases
Glomerular Filtration Rate
Serum
Multicenter Studies
Retrospective Studies
Kidney
Survival

Keywords

  • Acute kidney injury
  • Chemotherapy
  • Cisplatin
  • Serum creatinine
  • Urothelial cancer

ASJC Scopus subject areas

  • Physiology
  • Nephrology
  • Physiology (medical)

Cite this

Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients. / Ishitsuka, Ryutaro; Miyazaki, Jun; Ichioka, Daishi; Inoue, Takamitsu; Kageyama, Susumu; Sugimoto, Mikio; Mitsuzuka, Koji; Matsui, Yoshiyuki; Shiraishi, Yusuke; Kinoshita, Hidefumi; Wakeda, Hironobu; Nomoto, Takeshi; Kikuchi, Eiji; Kawai, Koji; Nishiyama, Hiroyuki.

In: Clinical and Experimental Nephrology, 26.08.2016, p. 1-9.

Research output: Contribution to journalArticle

Ishitsuka, R, Miyazaki, J, Ichioka, D, Inoue, T, Kageyama, S, Sugimoto, M, Mitsuzuka, K, Matsui, Y, Shiraishi, Y, Kinoshita, H, Wakeda, H, Nomoto, T, Kikuchi, E, Kawai, K & Nishiyama, H 2016, 'Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients', Clinical and Experimental Nephrology, pp. 1-9. https://doi.org/10.1007/s10157-016-1327-z
Ishitsuka, Ryutaro ; Miyazaki, Jun ; Ichioka, Daishi ; Inoue, Takamitsu ; Kageyama, Susumu ; Sugimoto, Mikio ; Mitsuzuka, Koji ; Matsui, Yoshiyuki ; Shiraishi, Yusuke ; Kinoshita, Hidefumi ; Wakeda, Hironobu ; Nomoto, Takeshi ; Kikuchi, Eiji ; Kawai, Koji ; Nishiyama, Hiroyuki. / Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients. In: Clinical and Experimental Nephrology. 2016 ; pp. 1-9.
@article{b595f95ea67040ab869f60a39067db72,
title = "Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients",
abstract = "Background: The Kidney Disease: Improving Global Outcomes group (KDIGO) defined acute kidney injury (AKI) as an elevation of serum creatinine (sCR) exceeding 0.3 mg/dl within 48 h. The widely used adverse events criteria for chemotherapy, Common Toxicity Criteria for Adverse Events Version 4.0 (CTCAE v4.0), also defined AKI as sCR exceeding 0.3 mg/dl, but with no provision of a time course. Here, we attempted to clarify the impact of AKI (CTCAE v4.0) during cisplatin-based chemotherapy on clinical outcome of patients with advanced urothelial cancer (UC). Methods: This multicenter retrospective study included 230 UC patients who received cisplatin-based chemotherapy. Results: During the first chemotherapy course, AKI (CTCAE v4.0) episodes were observed in 61 patients (26.5 {\%}), whereas only four patients (1.5 {\%}) experienced AKI (KDIGO) episodes. Both the pretreatment estimated glomerular filtration rate (eGFR) and creatinine clearance by Cockcroft–Gault formula were not efficient predictors for the development of AKI (CTCAE v4.0). AKI (CTCAE v4.0) impacted renal function: at the start of second-course chemotherapy, the average eGFR of the patients with AKI (CTCAE v4.0) was 54.1 ml/min/1.73 m2, significantly lower than that of patients without AKI (CTCAE v4.0) (63.4 ml/min/1.73 m2). As a result, only 57.4 {\%} of patients with AKI (CTCAE v4.0) received the planned treatment at the second course. The survival of the patients who developed AKI (CTCAE v4.0) was significantly worse than that of the patients who did not. The 3-year OSs were 10.3 and 21.4 {\%}, respectively (P = 0.02). Conclusion: The present study demonstrated that AKI (CTCAE v4.0) during chemotherapy had a negative impact on both the intensity of subsequent chemotherapy and oncological outcomes.",
keywords = "Acute kidney injury, Chemotherapy, Cisplatin, Serum creatinine, Urothelial cancer",
author = "Ryutaro Ishitsuka and Jun Miyazaki and Daishi Ichioka and Takamitsu Inoue and Susumu Kageyama and Mikio Sugimoto and Koji Mitsuzuka and Yoshiyuki Matsui and Yusuke Shiraishi and Hidefumi Kinoshita and Hironobu Wakeda and Takeshi Nomoto and Eiji Kikuchi and Koji Kawai and Hiroyuki Nishiyama",
year = "2016",
month = "8",
day = "26",
doi = "10.1007/s10157-016-1327-z",
language = "English",
pages = "1--9",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients

AU - Ishitsuka, Ryutaro

AU - Miyazaki, Jun

AU - Ichioka, Daishi

AU - Inoue, Takamitsu

AU - Kageyama, Susumu

AU - Sugimoto, Mikio

AU - Mitsuzuka, Koji

AU - Matsui, Yoshiyuki

AU - Shiraishi, Yusuke

AU - Kinoshita, Hidefumi

AU - Wakeda, Hironobu

AU - Nomoto, Takeshi

AU - Kikuchi, Eiji

AU - Kawai, Koji

AU - Nishiyama, Hiroyuki

PY - 2016/8/26

Y1 - 2016/8/26

N2 - Background: The Kidney Disease: Improving Global Outcomes group (KDIGO) defined acute kidney injury (AKI) as an elevation of serum creatinine (sCR) exceeding 0.3 mg/dl within 48 h. The widely used adverse events criteria for chemotherapy, Common Toxicity Criteria for Adverse Events Version 4.0 (CTCAE v4.0), also defined AKI as sCR exceeding 0.3 mg/dl, but with no provision of a time course. Here, we attempted to clarify the impact of AKI (CTCAE v4.0) during cisplatin-based chemotherapy on clinical outcome of patients with advanced urothelial cancer (UC). Methods: This multicenter retrospective study included 230 UC patients who received cisplatin-based chemotherapy. Results: During the first chemotherapy course, AKI (CTCAE v4.0) episodes were observed in 61 patients (26.5 %), whereas only four patients (1.5 %) experienced AKI (KDIGO) episodes. Both the pretreatment estimated glomerular filtration rate (eGFR) and creatinine clearance by Cockcroft–Gault formula were not efficient predictors for the development of AKI (CTCAE v4.0). AKI (CTCAE v4.0) impacted renal function: at the start of second-course chemotherapy, the average eGFR of the patients with AKI (CTCAE v4.0) was 54.1 ml/min/1.73 m2, significantly lower than that of patients without AKI (CTCAE v4.0) (63.4 ml/min/1.73 m2). As a result, only 57.4 % of patients with AKI (CTCAE v4.0) received the planned treatment at the second course. The survival of the patients who developed AKI (CTCAE v4.0) was significantly worse than that of the patients who did not. The 3-year OSs were 10.3 and 21.4 %, respectively (P = 0.02). Conclusion: The present study demonstrated that AKI (CTCAE v4.0) during chemotherapy had a negative impact on both the intensity of subsequent chemotherapy and oncological outcomes.

AB - Background: The Kidney Disease: Improving Global Outcomes group (KDIGO) defined acute kidney injury (AKI) as an elevation of serum creatinine (sCR) exceeding 0.3 mg/dl within 48 h. The widely used adverse events criteria for chemotherapy, Common Toxicity Criteria for Adverse Events Version 4.0 (CTCAE v4.0), also defined AKI as sCR exceeding 0.3 mg/dl, but with no provision of a time course. Here, we attempted to clarify the impact of AKI (CTCAE v4.0) during cisplatin-based chemotherapy on clinical outcome of patients with advanced urothelial cancer (UC). Methods: This multicenter retrospective study included 230 UC patients who received cisplatin-based chemotherapy. Results: During the first chemotherapy course, AKI (CTCAE v4.0) episodes were observed in 61 patients (26.5 %), whereas only four patients (1.5 %) experienced AKI (KDIGO) episodes. Both the pretreatment estimated glomerular filtration rate (eGFR) and creatinine clearance by Cockcroft–Gault formula were not efficient predictors for the development of AKI (CTCAE v4.0). AKI (CTCAE v4.0) impacted renal function: at the start of second-course chemotherapy, the average eGFR of the patients with AKI (CTCAE v4.0) was 54.1 ml/min/1.73 m2, significantly lower than that of patients without AKI (CTCAE v4.0) (63.4 ml/min/1.73 m2). As a result, only 57.4 % of patients with AKI (CTCAE v4.0) received the planned treatment at the second course. The survival of the patients who developed AKI (CTCAE v4.0) was significantly worse than that of the patients who did not. The 3-year OSs were 10.3 and 21.4 %, respectively (P = 0.02). Conclusion: The present study demonstrated that AKI (CTCAE v4.0) during chemotherapy had a negative impact on both the intensity of subsequent chemotherapy and oncological outcomes.

KW - Acute kidney injury

KW - Chemotherapy

KW - Cisplatin

KW - Serum creatinine

KW - Urothelial cancer

UR - http://www.scopus.com/inward/record.url?scp=84983770710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983770710&partnerID=8YFLogxK

U2 - 10.1007/s10157-016-1327-z

DO - 10.1007/s10157-016-1327-z

M3 - Article

C2 - 27565169

AN - SCOPUS:84983770710

SP - 1

EP - 9

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

ER -